Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert M Califf

Showing results (501-510 of 565) with videos related to

Pageof 57
Sort By:
Circulation. Cardiovascular Quality and Outcomes|June 14, 2013
End of study transition from study drug to open-label vitamin K antagonist therapy: the ROCKET AF experienceKenneth W Mahaffey, Anne S Hellkamp, Manesh R Patel, et al.
Journal of the American College of Cardiology|February 2, 2018
Improving Heart Failure Therapeutics Development in the United States: The Heart Failure CollaboratoryChristopher M O'Connor, Mitchell A Psotka, Mona Fiuzat, et al.
European Heart Journal|September 12, 2014
Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF TrialBenjamin A Steinberg, Anne S Hellkamp, Yuliya Lokhnygina, et al.
American Heart Journal|July 29, 2014
Prevalence, characteristics, and predictors of early termination of cardiovascular clinical trials due to low recruitment: insights from the ClinicalTrials.gov registrySabrina Bernardez-Pereira, Renato D Lopes, Maria Julia Machline Carrion, et al.
Journal of the American College of Cardiology|February 9, 2013
Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation)Manesh R Patel, Anne S Hellkamp, Yuliya Lokhnygina, et al.
Stroke|April 19, 2014
Intracranial hemorrhage among patients with atrial fibrillation anticoagulated with warfarin or rivaroxaban: the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillationGraeme J Hankey, Susanna R Stevens, Jonathan P Piccini, et al.
Journal of the American Heart Association|March 10, 2016
Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AFSean D Pokorney, Jonathan P Piccini, Susanna R Stevens, et al.
JAMA|August 10, 2002
Sertraline treatment of major depression in patients with acute MI or unstable anginaAlexander H Glassman, Christopher M O'Connor, Robert M Califf, et al.
JAMA|August 27, 2009
Sex differences in mortality following acute coronary syndromesJeffrey S Berger, Laine Elliott, Dianne Gallup, et al.
Journal of Cardiac Failure|February 18, 2014
High-sensitivity C-reactive protein in acute heart failure: insights from the ASCEND-HF trialAndreas P Kalogeropoulos, W H Wilson Tang, Amy Hsu, et al.
Pageof 57

Showing results (501-510 of 565) with videos related to

Sort By:
Pageof 57
Circulation. Cardiovascular Quality and Outcomes|June 14, 2013
End of study transition from study drug to open-label vitamin K antagonist therapy: the ROCKET AF experienceKenneth W Mahaffey, Anne S Hellkamp, Manesh R Patel, et al.
Journal of the American College of Cardiology|February 2, 2018
Improving Heart Failure Therapeutics Development in the United States: The Heart Failure CollaboratoryChristopher M O'Connor, Mitchell A Psotka, Mona Fiuzat, et al.
European Heart Journal|September 12, 2014
Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF TrialBenjamin A Steinberg, Anne S Hellkamp, Yuliya Lokhnygina, et al.
American Heart Journal|July 29, 2014
Prevalence, characteristics, and predictors of early termination of cardiovascular clinical trials due to low recruitment: insights from the ClinicalTrials.gov registrySabrina Bernardez-Pereira, Renato D Lopes, Maria Julia Machline Carrion, et al.
Journal of the American College of Cardiology|February 9, 2013
Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation)Manesh R Patel, Anne S Hellkamp, Yuliya Lokhnygina, et al.
Stroke|April 19, 2014
Intracranial hemorrhage among patients with atrial fibrillation anticoagulated with warfarin or rivaroxaban: the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillationGraeme J Hankey, Susanna R Stevens, Jonathan P Piccini, et al.
Journal of the American Heart Association|March 10, 2016
Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AFSean D Pokorney, Jonathan P Piccini, Susanna R Stevens, et al.
JAMA|August 10, 2002
Sertraline treatment of major depression in patients with acute MI or unstable anginaAlexander H Glassman, Christopher M O'Connor, Robert M Califf, et al.
JAMA|August 27, 2009
Sex differences in mortality following acute coronary syndromesJeffrey S Berger, Laine Elliott, Dianne Gallup, et al.
Journal of Cardiac Failure|February 18, 2014
High-sensitivity C-reactive protein in acute heart failure: insights from the ASCEND-HF trialAndreas P Kalogeropoulos, W H Wilson Tang, Amy Hsu, et al.
Pageof 57